Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ischemic Preconditioning, Myocardial | 8 | 2005 | 23 | 0.940 |
Why?
|
| Myocardial Ischemia | 5 | 2007 | 118 | 0.910 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2007 | 28 | 0.760 |
Why?
|
| Myocardium | 5 | 2007 | 274 | 0.660 |
Why?
|
| Insecticides | 3 | 2006 | 44 | 0.650 |
Why?
|
| Protein Precursors | 2 | 2007 | 83 | 0.550 |
Why?
|
| Receptors, Opioid | 2 | 2007 | 16 | 0.480 |
Why?
|
| Diazepam | 2 | 2006 | 10 | 0.470 |
Why?
|
| Dichlorvos | 2 | 2006 | 15 | 0.450 |
Why?
|
| Rats | 13 | 2007 | 1977 | 0.410 |
Why?
|
| Diphenhydramine | 2 | 2003 | 9 | 0.410 |
Why?
|
| Histamine H1 Antagonists | 2 | 2003 | 10 | 0.410 |
Why?
|
| Fluorocarbons | 4 | 2002 | 38 | 0.400 |
Why?
|
| Jejunum | 2 | 2002 | 14 | 0.390 |
Why?
|
| Liquid Ventilation | 2 | 2002 | 4 | 0.370 |
Why?
|
| Rabbits | 8 | 2006 | 332 | 0.360 |
Why?
|
| Hypothermia, Induced | 2 | 2001 | 39 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 4 | 2006 | 784 | 0.340 |
Why?
|
| Ischemia | 2 | 2002 | 204 | 0.340 |
Why?
|
| Pneumonia, Pneumococcal | 2 | 2002 | 28 | 0.330 |
Why?
|
| Animals | 27 | 2020 | 20613 | 0.320 |
Why?
|
| Management Quality Circles | 1 | 2009 | 2 | 0.320 |
Why?
|
| Organizational Case Studies | 1 | 2009 | 39 | 0.310 |
Why?
|
| Random Allocation | 6 | 2006 | 199 | 0.310 |
Why?
|
| Ursidae | 2 | 2020 | 12 | 0.310 |
Why?
|
| Enkephalin, Methionine | 2 | 2006 | 9 | 0.300 |
Why?
|
| Rats, Wistar | 8 | 2003 | 185 | 0.300 |
Why?
|
| Blood Transfusion | 2 | 1999 | 161 | 0.300 |
Why?
|
| Total Quality Management | 1 | 2008 | 56 | 0.290 |
Why?
|
| Enkephalins | 1 | 2007 | 20 | 0.280 |
Why?
|
| Opioid Peptides | 1 | 2007 | 4 | 0.280 |
Why?
|
| Efficiency, Organizational | 1 | 2008 | 96 | 0.280 |
Why?
|
| Naloxone | 3 | 2004 | 60 | 0.280 |
Why?
|
| Physical Exertion | 1 | 2007 | 79 | 0.270 |
Why?
|
| Trauma Centers | 1 | 2008 | 123 | 0.270 |
Why?
|
| Heart | 4 | 2007 | 282 | 0.270 |
Why?
|
| Glycopyrrolate | 2 | 2006 | 23 | 0.260 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 1092 | 0.260 |
Why?
|
| Disease Models, Animal | 9 | 2007 | 2179 | 0.260 |
Why?
|
| Xylazine | 1 | 2006 | 3 | 0.250 |
Why?
|
| Cardiotonic Agents | 1 | 2006 | 53 | 0.250 |
Why?
|
| Antidotes | 1 | 2006 | 21 | 0.250 |
Why?
|
| Morphine | 1 | 2006 | 59 | 0.240 |
Why?
|
| Ketamine | 1 | 2006 | 38 | 0.240 |
Why?
|
| Hypothermia | 2 | 2001 | 16 | 0.220 |
Why?
|
| Carotid Arteries | 2 | 2001 | 61 | 0.220 |
Why?
|
| Narcotics | 1 | 2004 | 58 | 0.220 |
Why?
|
| Apnea | 1 | 2004 | 32 | 0.220 |
Why?
|
| Gene Expression Profiling | 1 | 2007 | 765 | 0.220 |
Why?
|
| Muscle Relaxants, Central | 1 | 2003 | 12 | 0.210 |
Why?
|
| Tobramycin | 1 | 2003 | 7 | 0.210 |
Why?
|
| Organophosphorus Compounds | 1 | 2003 | 31 | 0.210 |
Why?
|
| In Vitro Techniques | 5 | 2002 | 487 | 0.210 |
Why?
|
| Klebsiella Infections | 1 | 2003 | 22 | 0.210 |
Why?
|
| Hibernation | 2 | 2020 | 10 | 0.210 |
Why?
|
| Neutron Activation Analysis | 1 | 2003 | 3 | 0.200 |
Why?
|
| Ventricular Fibrillation | 2 | 2001 | 106 | 0.200 |
Why?
|
| Iohexol | 1 | 2003 | 16 | 0.200 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 34 | 0.200 |
Why?
|
| Organophosphate Poisoning | 1 | 2002 | 14 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 89 | 0.200 |
Why?
|
| Central Nervous System Diseases | 1 | 2003 | 57 | 0.200 |
Why?
|
| Enkephalin, Leucine-2-Alanine | 1 | 2002 | 2 | 0.200 |
Why?
|
| Receptors, Opioid, delta | 1 | 2002 | 5 | 0.200 |
Why?
|
| Potassium Channels | 1 | 2002 | 58 | 0.190 |
Why?
|
| Vaccines | 1 | 2023 | 96 | 0.190 |
Why?
|
| Swine | 4 | 2007 | 370 | 0.190 |
Why?
|
| Arm Injuries | 1 | 2001 | 12 | 0.190 |
Why?
|
| Leg Injuries | 1 | 2001 | 16 | 0.190 |
Why?
|
| Reperfusion Injury | 1 | 2002 | 53 | 0.190 |
Why?
|
| Myocardial Reperfusion | 4 | 2006 | 24 | 0.190 |
Why?
|
| Respiratory Insufficiency | 1 | 2003 | 155 | 0.180 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2007 | 619 | 0.180 |
Why?
|
| Ventricular Function, Left | 2 | 2000 | 270 | 0.180 |
Why?
|
| Rewarming | 1 | 2001 | 6 | 0.180 |
Why?
|
| Resuscitation | 1 | 2001 | 67 | 0.180 |
Why?
|
| Hemostasis | 1 | 2020 | 18 | 0.170 |
Why?
|
| Coronary Vessels | 2 | 2009 | 118 | 0.170 |
Why?
|
| Patient Discharge | 1 | 2024 | 510 | 0.170 |
Why?
|
| Pharmaceutical Services | 1 | 2020 | 33 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 56 | 0.170 |
Why?
|
| Pain Measurement | 1 | 2001 | 345 | 0.170 |
Why?
|
| Patient Readmission | 1 | 2024 | 430 | 0.160 |
Why?
|
| Femoral Artery | 1 | 2001 | 110 | 0.160 |
Why?
|
| Ischemic Preconditioning | 1 | 1999 | 8 | 0.160 |
Why?
|
| RNA, Viral | 1 | 2021 | 276 | 0.160 |
Why?
|
| Norepinephrine | 1 | 1999 | 102 | 0.160 |
Why?
|
| Adenosine | 1 | 1999 | 78 | 0.160 |
Why?
|
| Drug Utilization | 1 | 2020 | 208 | 0.150 |
Why?
|
| Accountable Care Organizations | 1 | 2020 | 67 | 0.150 |
Why?
|
| Narcotic Antagonists | 3 | 2007 | 136 | 0.150 |
Why?
|
| Myocardial Infarction | 3 | 2001 | 913 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 860 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 149 | 0.150 |
Why?
|
| Pain | 1 | 2001 | 404 | 0.150 |
Why?
|
| Male | 17 | 2024 | 29717 | 0.150 |
Why?
|
| Blood Coagulation | 1 | 2017 | 39 | 0.130 |
Why?
|
| Respiration, Artificial | 2 | 1999 | 297 | 0.120 |
Why?
|
| Hemodynamics | 3 | 2001 | 248 | 0.120 |
Why?
|
| Prospective Studies | 4 | 2003 | 3270 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2009 | 432 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2003 | 1143 | 0.110 |
Why?
|
| Muscle, Smooth | 2 | 2007 | 134 | 0.110 |
Why?
|
| MicroRNAs | 1 | 2020 | 674 | 0.110 |
Why?
|
| Humans | 16 | 2024 | 63149 | 0.100 |
Why?
|
| Brain | 2 | 2003 | 1553 | 0.100 |
Why?
|
| RNA, Messenger | 2 | 2007 | 1536 | 0.090 |
Why?
|
| Perfusion | 3 | 2000 | 72 | 0.090 |
Why?
|
| Body Temperature | 2 | 2001 | 45 | 0.090 |
Why?
|
| Muscle Contraction | 2 | 2002 | 202 | 0.090 |
Why?
|
| Analysis of Variance | 2 | 2001 | 608 | 0.080 |
Why?
|
| Connective Tissue | 1 | 2009 | 12 | 0.080 |
Why?
|
| Time Factors | 3 | 2009 | 3754 | 0.080 |
Why?
|
| Hospitals, Community | 1 | 2009 | 71 | 0.080 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 105 | 0.080 |
Why?
|
| Midwestern United States | 1 | 2008 | 25 | 0.070 |
Why?
|
| Organizational Innovation | 1 | 2009 | 82 | 0.070 |
Why?
|
| Intra-Abdominal Fat | 1 | 2009 | 34 | 0.070 |
Why?
|
| Vascular Surgical Procedures | 2 | 2001 | 261 | 0.070 |
Why?
|
| Seasons | 2 | 2020 | 134 | 0.070 |
Why?
|
| Hospitals, Rural | 1 | 2008 | 19 | 0.070 |
Why?
|
| Subcutaneous Fat | 1 | 2009 | 47 | 0.070 |
Why?
|
| Health Plan Implementation | 1 | 2008 | 40 | 0.070 |
Why?
|
| Poisoning | 2 | 2006 | 32 | 0.070 |
Why?
|
| Adipogenesis | 1 | 2009 | 79 | 0.070 |
Why?
|
| Dietary Fats | 1 | 2009 | 175 | 0.070 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 176 | 0.070 |
Why?
|
| Epithelium | 1 | 2007 | 96 | 0.070 |
Why?
|
| Kidney | 2 | 2007 | 444 | 0.070 |
Why?
|
| Pandemics | 2 | 2023 | 672 | 0.070 |
Why?
|
| Models, Animal | 2 | 2009 | 236 | 0.070 |
Why?
|
| Aging | 2 | 2005 | 746 | 0.070 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 234 | 0.070 |
Why?
|
| Naltrexone | 1 | 2007 | 89 | 0.070 |
Why?
|
| United States | 4 | 2021 | 7824 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2007 | 451 | 0.060 |
Why?
|
| Intestines | 1 | 2007 | 167 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 607 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 542 | 0.060 |
Why?
|
| Adipocytes | 1 | 2009 | 268 | 0.060 |
Why?
|
| Injections, Intramuscular | 1 | 2006 | 71 | 0.060 |
Why?
|
| Hospitalization | 1 | 2013 | 1356 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 5429 | 0.060 |
Why?
|
| Cystitis | 1 | 2005 | 10 | 0.060 |
Why?
|
| Staphylococcus | 1 | 2005 | 17 | 0.060 |
Why?
|
| Reference Values | 1 | 2006 | 335 | 0.060 |
Why?
|
| Intestinal Mucosa | 1 | 2007 | 245 | 0.060 |
Why?
|
| Gram-Negative Bacteria | 1 | 2005 | 57 | 0.060 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2005 | 41 | 0.060 |
Why?
|
| Length of Stay | 1 | 2009 | 808 | 0.060 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2006 | 56 | 0.060 |
Why?
|
| Female | 7 | 2024 | 32709 | 0.060 |
Why?
|
| Massachusetts | 2 | 2021 | 2073 | 0.060 |
Why?
|
| Urinary Tract Infections | 1 | 2006 | 91 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2020 | 2560 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2005 | 149 | 0.060 |
Why?
|
| Middle Aged | 4 | 2020 | 17480 | 0.060 |
Why?
|
| Aged | 4 | 2024 | 14333 | 0.060 |
Why?
|
| Transitional Care | 1 | 2024 | 25 | 0.060 |
Why?
|
| Gene Expression | 1 | 2007 | 837 | 0.050 |
Why?
|
| Inflammation | 2 | 2009 | 1144 | 0.050 |
Why?
|
| Allied Health Personnel | 1 | 2024 | 30 | 0.050 |
Why?
|
| Intubation | 1 | 2003 | 11 | 0.050 |
Why?
|
| Mass Vaccination | 1 | 2023 | 10 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 2 | 2009 | 3387 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2024 | 109 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2003 | 30 | 0.050 |
Why?
|
| Klebsiella pneumoniae | 1 | 2003 | 28 | 0.050 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2003 | 55 | 0.050 |
Why?
|
| Ipratropium | 1 | 2003 | 7 | 0.050 |
Why?
|
| Xenon Isotopes | 1 | 2003 | 3 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2003 | 52 | 0.050 |
Why?
|
| Iodine | 1 | 2003 | 19 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2003 | 34 | 0.050 |
Why?
|
| Glyburide | 1 | 2002 | 9 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2002 | 11 | 0.050 |
Why?
|
| Mesentery | 1 | 2002 | 15 | 0.050 |
Why?
|
| Potassium Channel Blockers | 1 | 2002 | 27 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 1 | 2003 | 113 | 0.050 |
Why?
|
| Splanchnic Circulation | 1 | 2002 | 16 | 0.050 |
Why?
|
| Muscle, Skeletal | 1 | 2007 | 738 | 0.050 |
Why?
|
| Hydrocarbons, Brominated | 1 | 2002 | 4 | 0.050 |
Why?
|
| Apoptosis | 1 | 2007 | 1073 | 0.050 |
Why?
|
| Infusions, Parenteral | 1 | 2002 | 22 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2024 | 564 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2002 | 228 | 0.050 |
Why?
|
| Enkephalin, Leucine | 1 | 2001 | 7 | 0.050 |
Why?
|
| Radioimmunoassay | 1 | 2001 | 63 | 0.050 |
Why?
|
| Epinephrine | 1 | 2001 | 44 | 0.050 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 213 | 0.050 |
Why?
|
| Hypoxia | 1 | 2002 | 115 | 0.040 |
Why?
|
| Phenylpropanolamine | 1 | 2001 | 2 | 0.040 |
Why?
|
| Phentolamine | 1 | 2001 | 7 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 20 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 2001 | 18 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 371 | 0.040 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2001 | 16 | 0.040 |
Why?
|
| Escherichia coli | 1 | 2006 | 700 | 0.040 |
Why?
|
| Vaccination | 1 | 2023 | 363 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2024 | 1004 | 0.040 |
Why?
|
| Antithrombin III | 1 | 2020 | 14 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2001 | 195 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2020 | 54 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 579 | 0.040 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 30 | 0.040 |
Why?
|
| Body Weight | 1 | 2001 | 377 | 0.040 |
Why?
|
| Heart Rate | 1 | 2001 | 321 | 0.040 |
Why?
|
| Coronary Circulation | 1 | 1999 | 52 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2020 | 373 | 0.040 |
Why?
|
| Kerosene | 1 | 1999 | 1 | 0.040 |
Why?
|
| Glucose | 1 | 2002 | 467 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 171 | 0.040 |
Why?
|
| Models, Cardiovascular | 1 | 1999 | 79 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2001 | 509 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2001 | 264 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2020 | 217 | 0.040 |
Why?
|
| Penicillin G | 1 | 1998 | 5 | 0.040 |
Why?
|
| Adolescent | 3 | 2006 | 6229 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 394 | 0.040 |
Why?
|
| Mice | 2 | 2009 | 10816 | 0.030 |
Why?
|
| Brain Ischemia | 1 | 2001 | 417 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 1559 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2001 | 1543 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2020 | 1461 | 0.030 |
Why?
|
| Treatment Outcome | 1 | 2006 | 5625 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2020 | 6595 | 0.030 |
Why?
|
| Rats, Inbred F344 | 2 | 2005 | 53 | 0.030 |
Why?
|
| Triage | 1 | 2013 | 125 | 0.020 |
Why?
|
| Patient Admission | 1 | 2013 | 193 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2006 | 1355 | 0.020 |
Why?
|
| Adult | 2 | 2013 | 16736 | 0.020 |
Why?
|
| Infant | 2 | 2006 | 1649 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 1082 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2006 | 1988 | 0.020 |
Why?
|
| Cell Shape | 1 | 2009 | 12 | 0.020 |
Why?
|
| CCAAT-Enhancer-Binding Protein-alpha | 1 | 2009 | 14 | 0.020 |
Why?
|
| Fatty Acid-Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 57 | 0.020 |
Why?
|
| Adiponectin | 1 | 2009 | 36 | 0.020 |
Why?
|
| Interleukin-8 | 1 | 2009 | 88 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2009 | 81 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 76 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2009 | 118 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2009 | 320 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2009 | 153 | 0.020 |
Why?
|
| Child | 2 | 2006 | 4520 | 0.020 |
Why?
|
| Okadaic Acid | 1 | 2005 | 9 | 0.020 |
Why?
|
| Protein Phosphatase 2 | 1 | 2005 | 10 | 0.020 |
Why?
|
| Phenotype | 1 | 2009 | 1199 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2009 | 2152 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 284 | 0.010 |
Why?
|
| Acute Disease | 1 | 2005 | 671 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2005 | 373 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2005 | 311 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2005 | 937 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2009 | 1614 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 2001 | 47 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2000 | 88 | 0.010 |
Why?
|
| Longevity | 1 | 2001 | 113 | 0.010 |
Why?
|
| Necrosis | 1 | 2000 | 143 | 0.010 |
Why?
|
| Administration, Inhalation | 1 | 1999 | 151 | 0.010 |
Why?
|
| Intubation, Intratracheal | 1 | 1999 | 204 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 3033 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1999 | 1645 | 0.010 |
Why?
|